HAE news

Haemonetics increased Q1 FY27 revenue 5.6% and adjusted earnings per share to $1.14; the company raised total company fiscal 2027 guidance driven by strong business momentum.

Haemonetics has amended and restated its 2019 Long-Term Incentive Compensation Plan to adjust employee, director, and consultant compensation awards. This aligns the economic interests of participants with those of stockholders.

Haemonetics is consolidating its three reportable segments into two: combining Plasma and Blood Center into Apheresis, and renaming Hospital to MedSurg, effective Q1 fiscal 2027. The restructuring aligns external financial reporting with internal business management while maintaining supplemental re…